Clinical Trial News and Research

RSS

22nd Century initiates enrollment in Phase II-B clinical trial of X-22 for smoking cessation

22nd Century Group, Inc., a company focused on smoking cessation and tobacco harm reduction products, today announced that its wholly-owned subsidiary, 22nd Century Limited, LLC, enrolled the first patients in its Phase II-B clinical trial for X-22, a prescription smoking cessation aid in development.

8 Aug 2011

AMRI second quarter total revenue increases 9% to $53.9 million

AMRI today reported financial and operating results for the second quarter ended June 30, 2011.

8 Aug 2011

Inhibitex second quarter net loss decreases to $5.3 million

Inhibitex, Inc. today announced its financial results for the second quarter ended June 30, 2011 and provided an update on several recent clinical and corporate developments.

8 Aug 2011

ADVENTRX's second quarter net loss decreases to $4.4 million

ADVENTRX Pharmaceuticals, Inc. today reported financial results for the periods ended June 30, 2011.

8 Aug 2011

Insmed second quarter revenues decrease to $1.0 million

Insmed Incorporated, a biopharmaceutical company, today reported results for the second quarter and six-months ended June 30, 2011.

8 Aug 2011

Head and neck melanoma patients can benefit from sentinel lymph node biopsy

A common technique for determining whether melanoma has spread can be used safely and effectively even in tumors from the head and neck area, according to a new study from the University of Michigan Comprehensive Cancer Center.

6 Aug 2011

Clinical trial to assess impact of dietary change in men with prostate cancer

Two researchers from Roswell Park Cancer Institute (RPCI) have opened a clinical trial that will assess the impact of dietary change to control prostate cancer.

6 Aug 2011

Idera second quarter net loss increases to $6.3 million

Idera Pharmaceuticals, Inc. today reported financial results for the second quarter ended June 30, 2011. Idera is a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-Like receptors (TLRs).

5 Aug 2011

GenMark Diagnostics second quarter revenues increase to $901,000

GenMark Diagnostics, Inc. today reported financial results for the second quarter ended June 30, 2011.

5 Aug 2011

Longer looks: Treating Down syndrome?; mentally ill, meds & trials

Politicians want to lower spending, or at least they say they do. But in all the to-and-fro over raising the debt ceiling, little sensible has been said about lowering spending in the long term. Nothing illuminates this more clearly than health care.

5 Aug 2011

FDA approves first scorpion antivenom

The U.S. Food and Drug Administration today approved Anascorp-, an antivenom produced in Mexico and tested in clinical trials conducted through the University of Arizona, for use in treating patients suffering the effects of scorpion sting.

5 Aug 2011

FDA grants Orphan Drug Designation to Kamada's AAT product for type 1 diabetes

Kamada LTD., a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, was granted an Orphan Drug Designation for its Alpha-1 Antitrypsin (AAT) product to treat type 1 diabetes.

5 Aug 2011

OncoGenex second quarter revenue increases to $1.9 million

OncoGenex Pharmaceuticals, Inc. today provided an update on current events and activities and announced its second quarter financial results.

5 Aug 2011

Palatin confirms initiation of AZD2820 Phase 1 trial in obesity

Palatin Technologies, Inc. confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity.

4 Aug 2011

RNAi screen identifies Brd4 as a therapeutic target for acute myeloid leukemia

Scientists at Cold Spring Harbor Laboratory (CSHL) and five other institutions have used an unconventional approach to cancer drug discovery to identify a new potential treatment for acute myeloid leukemia.

4 Aug 2011

Micromet second quarter total revenues increase to $7.1 million

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced its financial results for the second quarter and six months ended June 30, 2011.

4 Aug 2011

Columbia Laboratories second quarter total net revenues increase to $19.2 million

Columbia Laboratories, Inc. today reported financial results for the three- and six-month periods ended June 30, 2011.

4 Aug 2011

Positive results from hGH-CTP Phase II trial in growth hormone deficient adults

PROLOR Biotech, Inc. today reported positive results from a Phase II clinical trial of its long-acting CTP-modified version of human growth hormone (hGH-CTP) in growth hormone deficient adults.

4 Aug 2011

NIH-funded study to assess biomarkers in the blood of TBI patients

Biomarkers in the bloodstream could provide physicians with a quick and accurate method of assessing the severity of traumatic brain injury (TBI) and helping deliver and monitor the results of therapies, such as progesterone treatment.

4 Aug 2011

Acceleron, Celgene enter development collaboration for ACE-536 protein therapeutic to treat anemia

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, and Celgene Corporation today announced that the companies have entered into a joint development and commercialization agreement for ACE-536 for the treatment of anemia.

3 Aug 2011